Kaya Holdings, Inc.
Kaya Holdings, Inc. is a U.S.-based cannabis and emerging psychedelics operator that runs retail sales, cultivation-related projects, and service activities through a network of majority-owned subsidiaries. The company also has a newer digital-assets treasury initiative, but its current business remains centered on cash-and-carry cannabis retail and development-stage cannabis/psychedelic operations.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueCash-and-carry sales of cannabis products through licensed retail locations.
Development-stage cultivation, extraction, packing, and related infrastructure projects, mainly in Greece.
OHA-licensed psilocybin service center activities and related facilitation services.
Contract-based revenue from licensing agreements and pilot studies.
ATM transaction fees and other small ancillary revenue streams at operating sites.
Customers
Kaya sells primarily to adult-use cannabis consumers at licensed retail stores, where transactions are completed immediately in cash or card for services. It also targets medical cannabis and future international cannabis customers through its Greek subsidiary, while its psychedelic service center is aimed at patients or clients seeking regulated psilocybin facilitation services. Smaller revenue streams come from counterparties in licensing, pilot-study, and ATM-service arrangements.
Buy cannabis products at licensed stores on a cash-and-carry basis for immediate consumption or use.
Buy cultivation, extraction, and processing output from the company's overseas cannabis platform as it develops.
Purchase regulated psilocybin facilitation services at the company's licensed service center.
Enter contracts for product commercialization, licensing, or pilot studies tied to the company's development pipeline.
Provide ancillary fee income from ATM transactions at retail locations.
Strategy
Management is trying to fund and complete its growth projects while sustaining current retail operations and preserving liquidity. The strategy combines domestic cash-generating cannabis retail with overseas cannabis expansion in Greece, plus a newer psychedelic-treatment platform and a digital-assets treasury initiative. Near-term execution depends heavily on raising capital and converting development assets into operating revenue.
The company needs financing to fund operations, complete projects, and bridge working-capital deficits.
The Epidaurus site could add cultivation, extraction, and packing capacity if financed and completed.
This creates a second regulated healthcare-adjacent growth avenue beyond cannabis retail.
Management is adding new platforms to reduce dependence on a narrow retail base.
Geography
Kaya is headquartered in the United States and operates mainly through Florida, Oregon, and other U.S. subsidiaries, with additional exposure to Israel and Greece through majority-owned international entities. Its Greece project is a major strategic geography, designed for cultivation, extraction, and packing, but it remains development-stage and dependent on financing. The company also has a newly formed crypto operations subsidiary in Florida, though that initiative is still early.
Risks
Kaya faces substantial going-concern, financing, and execution risk because it has limited cash, a working-capital deficit, and development projects that require outside funding. Its cannabis operations are exposed to regulatory constraints, Section 280E tax treatment, and volatile pricing and competition, while the international project pipeline adds geopolitical and project-completion risk. The company also depends on successful commercialization of new products and services that are still early in their lifecycle.
- Going-concern / business failure riskImpact: CriticalLikelihood: High
The company disclosed limited cash and a working-capital deficiency, making continued operations dependent on new funding.
Exposure: Corporate liquidity and all operating subsidiaries
- Financing and dilution riskImpact: HighLikelihood: High
Operations and project completion rely on future equity or debt raises, which may be unavailable or highly dilutive.
Exposure: Expansion projects and general working capital
- Cannabis regulatory and tax riskImpact: HighLikelihood: Low
Cannabis operations are subject to changing state/federal rules and Section 280E limits on deductions.
Exposure: U.S. cannabis retail and related discontinued cannabis activities
- Commercialization riskImpact: MediumLikelihood: High
Management cited uncertainty around product commercialization and ultimate success.
Exposure - Geopolitical / project-delivery riskImpact: MediumLikelihood: Medium
The Greece project has already been delayed by COVID-19 and the Russia/Ukraine war, showing external disruption risk.
Exposure - Competition and pricing pressureImpact: MediumLikelihood: Low
Retail cannabis markets are competitive and product pricing can be volatile, pressuring margins.
Exposure: Cannabis retail operations
Accounting
Judgemental itemsRetail sales are recognized only when product is delivered and paid for, making reported revenue sensitive to store traffic and cash collection.
Impact: Quarterly revenue can be volatile and highly dependent on transaction timing.
Cost of sales includes product purchases and third-party testing, which directly affects gross margin in a price-competitive market.
Impact: Margin volatility if product costs or testing costs rise.
The company records original issue discounts and amortizes them to interest expense, which can materially increase reported financing costs.
Impact: Higher non-cash interest expense and dilution from conversions.
Equity awards are measured at fair value and expensed over service periods, affecting operating losses.
Impact: Non-cash compensation can materially widen reported losses.
Cannabis-related operations may face limited deductibility of expenses, creating tax provisions even with net operating losses.
Impact: Tax expense may not track pre-tax profitability.
Similar listed companies
Publicly listed companies with a comparable business focus.
Ayr Wellness Inc.
AYRWF · Medicinal Chemicals & Botanical Products
Verano Holdings Corp.
VRNO · Agricultural Production-Crops
Target Group Inc.
CBDY · Medicinal Chemicals & Botanical Products
Planet 13 Holdings Inc.
PLNH · Agricultural Production-Crops
Canton Strategic Holdings, Inc.
CNTN · Finance Services
Charlie's Holdings, Inc.
CHUC · Medicinal Chemicals & Botanical Products
Last updated: 24/09/2026